Evidence and guidelines are becoming increasingly clear about imbalance between the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed with – according to Belgian market research data – up to 70% of patients in current practice receiving ICSs, usually as a fixed combination with a long-acting β2-adrenoreceptor agonist. Studies and recommendations support withdrawal of ICSs in a large group of patients with COPD. However, historical habits appear difficult to change even in the light of recent scientific evidence. We have built a collaborative educational platform with chest physicians and primary care physicians to increase awareness and provide guidance and support in this matter.
- Inhaled steroids
- Systematic review
Cataldo, D., Derom, E., Liistro, G., Marchand, É., Ninane, V., Peché, R., Slabbynck, H., Vincken, W., & Janssens, W. (2018). Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. International Journal of COPD, 13, 2089-2099. https://doi.org/10.2147/COPD.S164259